a signature that is consistent with efficacy F
Post# of 148278
First GILD REMD was " trending " now Plasma gives us a signal.
The only good news, the FDA is bending over backwards to let everyone try whatever they want to try. In times of desperation give the families hope and the desire to keep fighting.
Anyway,
Conclusion
The relationships between mortality and both time to plasma transfusion, and antibody
levels provide a signature that is consistent with efficacy for the use of convalescent
plasma in the treatment of hospitalized COVID-19 patients.